Programmable longevity, engineered at cellular resolution.
We build gene circuits that clear senescent cells on a schedule. Fourteen candidate payloads are in vivo across three murine cohorts, with median lifespan extension of 42.8% and no observed off-target toxicity.
A closed loop from construct to biological age.
Design, express, assay, re-rank — the loop closes in 11 days. Click a step, or keep scrolling.
Circuit design
Promoter–payload pairs are composed in silico, then ranked by predicted senolytic selectivity.
14 candidates rankedAutomated assay
Every candidate runs the same cytometry and qPCR battery, no manual curation.
3,240 events / gateEpigenetic readout
Methylation clocks read biological age directly, so efficacy is measured, not inferred.
11-day loop close
01 / 03
Circuit design
Promoter–payload pairs are composed in silico, then ranked by predicted senolytic selectivity.
The circuit sits dormant inside the cell.
AG-118 is delivered as a silent construct. In a healthy cell the promoter never fires — the payload stays inert and the cell is left untouched.
0 off-target events / 3,240 gatedThe instrument our own biologists run on.
Every figure on this page is queried from Lumen. Move through the screens below — the data is live from the current cohort.
Four programmes, one assay backbone.
Lead programme. Phase I dosing complete in 18 subjects; no dose-limiting toxicity observed. Next gate: interim biomarker readout at week 24.
Toxicology package underway ahead of the IND submission. Thymic mass recovery of 34% observed at 12 weeks in the aged cohort.
Delivery efficiency below target in the current vector generation; a re-engineered capsid is in construction. Timeline under review.
Earliest-stage programme. Four reprogramming factor combinations are being screened for senescence reversal without loss of cell identity.
The numbers are the argument.
Every figure below is drawn from the same three cohorts and is reproduced in the preprint. Uncertainty is stated, not smoothed.
p16INK4a+ burden in hepatic tissue, 24 weeks post-administration. Investigational. Not approved for human use.
We are raising to take AG-118 into first-in-human.
The data room contains full cohort records, construct maps, and the IND-enabling plan. Access is granted to institutional investors under NDA.